Logo image of SLRX

SALARIUS PHARMACEUTICALS INC (SLRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLRX - US79400X5032 - Common Stock

0.636 USD
-0.02 (-2.48%)
Last: 12/24/2025, 8:01:21 PM
0.641 USD
+0.01 (+0.79%)
After Hours: 12/24/2025, 8:01:21 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to SLRX. SLRX was compared to 530 industry peers in the Biotechnology industry. While SLRX seems to be doing ok healthwise, there are quite some concerns on its profitability. SLRX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SLRX has reported negative net income.
In the past year SLRX has reported a negative cash flow from operations.
In the past 5 years SLRX always reported negative net income.
In the past 5 years SLRX always reported negative operating cash flow.
SLRX Yearly Net Income VS EBIT VS OCF VS FCFSLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of SLRX (-82.03%) is worse than 69.25% of its industry peers.
SLRX has a Return On Equity (-117.74%) which is in line with its industry peers.
Industry RankSector Rank
ROA -82.03%
ROE -117.74%
ROIC N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
SLRX Yearly ROA, ROE, ROICSLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

SLRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLRX Yearly Profit, Operating, Gross MarginsSLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLRX has more shares outstanding
SLRX has more shares outstanding than it did 5 years ago.
SLRX has a worse debt/assets ratio than last year.
SLRX Yearly Shares OutstandingSLRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20K 40K 60K 80K
SLRX Yearly Total Debt VS Total AssetsSLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -20.22, we must say that SLRX is in the distress zone and has some risk of bankruptcy.
SLRX has a Altman-Z score of -20.22. This is amonst the worse of the industry: SLRX underperforms 84.15% of its industry peers.
There is no outstanding debt for SLRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.22
ROIC/WACCN/A
WACCN/A
SLRX Yearly LT Debt VS Equity VS FCFSLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

A Current Ratio of 3.28 indicates that SLRX has no problem at all paying its short term obligations.
SLRX has a worse Current ratio (3.28) than 61.51% of its industry peers.
SLRX has a Quick Ratio of 3.28. This indicates that SLRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.28, SLRX is in line with its industry, outperforming 41.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
SLRX Yearly Current Assets VS Current LiabilitesSLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 68.10% over the past year.
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.17% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLRX Yearly Revenue VS EstimatesSLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2026 2M 4M 6M 8M 10M
SLRX Yearly EPS VS EstimatesSLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 -50K -100K -150K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLRX. In the last year negative earnings were reported.
Also next year SLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLRX Price Earnings VS Forward Price EarningsSLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLRX Per share dataSLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

SLRX's earnings are expected to decrease with -3.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SALARIUS PHARMACEUTICALS INC

NASDAQ:SLRX (12/24/2025, 8:01:21 PM)

After market: 0.641 +0.01 (+0.79%)

0.636

-0.02 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners5.17%
Inst Owner Change-99.37%
Ins Owners0.64%
Ins Owner Change4.17%
Market Cap3.73M
Revenue(TTM)N/A
Net Income(TTM)-5.00M
Analysts43.33
Price TargetN/A
Short Float %3.17%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-39.18
EYN/A
EPS(NY)-4.39
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.76
OCFYN/A
SpS0
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.03%
ROE -117.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-196.87%
ROA(5y)-130.59%
ROE(3y)-303.46%
ROE(5y)-195.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z -20.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.08%
EPS Next Y-126.98%
EPS Next 2Y-3.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.38%
OCF growth 3YN/A
OCF growth 5YN/A

SALARIUS PHARMACEUTICALS INC / SLRX FAQ

Can you provide the ChartMill fundamental rating for SALARIUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 1 / 10 to SLRX.


What is the valuation status of SALARIUS PHARMACEUTICALS INC (SLRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to SALARIUS PHARMACEUTICALS INC (SLRX). This can be considered as Overvalued.


What is the profitability of SLRX stock?

SALARIUS PHARMACEUTICALS INC (SLRX) has a profitability rating of 0 / 10.


How financially healthy is SALARIUS PHARMACEUTICALS INC?

The financial health rating of SALARIUS PHARMACEUTICALS INC (SLRX) is 5 / 10.


Can you provide the dividend sustainability for SLRX stock?

The dividend rating of SALARIUS PHARMACEUTICALS INC (SLRX) is 0 / 10 and the dividend payout ratio is 0%.